![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Designates Renovia’s Leva Digital Therapeutic for Incontinence a Breakthrough
FDA Designates Renovia’s Leva Digital Therapeutic for Incontinence a Breakthrough
Renovia has received a Breakthrough Device designation from the FDA for its leva Digital Therapeutic System as a first-line treatment for chronic fecal incontinence in women.
The system is a small wand combined with a smartphone app that offers a drug-free way for women to train and strengthen their pelvic floor muscles. The treatment can be done at home and takes just five minutes a day, Renovia said.
The device already has 510(k) clearance to treat urinary incontinence in women, according to the Boston, Mass.-based company, which specializes in developing digital therapeutics for female pelvic floor disorders.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct